Park Hotels & Resorts Inc.(PK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PK Park Hotels & Resorts Inc.

Not Yet Opened 12-29 16:00:00 EST

10.82

-0.02

-0.18%

盘后10.90

+0.08+0.74%

19:56 EST

High10.94	Low10.77	Vol3.16M
Open10.87	D1 Closing10.84	Amplitude1.57%
Mkt Cap2.16B	Tradable Cap2.12B	Total Shares199.90M
T/O34.18M	T/O Rate1.61%	Tradable Shares195.63M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PK","market":"US","secType":"STK","nameCN":"Park Hotels & Resorts Inc.","latestPrice":10.82,"timestamp":1767042000000,"preClose":10.84,"halted":0,"volume":3156832,"hourTrading":{"tag":"盘后","latestPrice":10.8999,"preClose":10.82,"latestTime":"19:56 EST","volume":188776,"amount":2042626.6975,"timestamp":1767056205338},"delay":0,"floatShares":195633448,"shares":199898278,"eps":-0.0701,"marketStatus":"Not Yet Opened","change":-0.02,"latestTime":"12-29 16:00:00 EST","open":10.87,"high":10.94,"low":10.77,"amount":34176614.558016,"amplitude":0.015683,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0701,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1767085200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":10.84,"dividendRate":0.12939,"preHourTrading":{"tag":"盘前","latestPrice":10.93,"preClose":10.84,"latestTime":"09:29 EST","volume":3304,"amount":35961.905616000004,"timestamp":1767018599999},"postHourTrading":{"tag":"盘后","latestPrice":10.8999,"preClose":10.82,"latestTime":"19:56 EST","volume":188776,"amount":2042626.6975,"timestamp":1767056205338},"volumeRatio":1.151052,"impliedVol":0.2212,"impliedVolPercentile":0.116},"requestUrl":"/m/hq/s/PK/tweets","defaultTab":"tweets","newsList":[{"id":"2593444292","title":"U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2593444292","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593444292?lang=en_us&edition=fundamental","pubTime":"2025-12-24 08:45","pubTimestamp":1766537100,"startTime":"0","endTime":"0","summary":"AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemiaMarketed under AQVESME brand name in the U.S. for thalassemia","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/24/3210205/31990/en/U-S-FDA-Approves-Agios-AQVESME-mitapivat-for-the-Treatment-of-Anemia-in-Adults-with-Alpha-or-Beta-Thalassemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","IE00BLDYK493.USD","BK4161","RBC","LU2065731478.USD","BK4181","PK","BK4218","IE00B64QTZ34.USD","HCI"],"gpt_icon":0},{"id":"2593412376","title":"Assessing Park Hotels & Resorts (PK) Valuation After Recent Share Price Underperformance","url":"https://stock-news.laohu8.com/highlight/detail?id=2593412376","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593412376?lang=en_us&edition=fundamental","pubTime":"2025-12-23 22:18","pubTimestamp":1766499487,"startTime":"0","endTime":"0","summary":"Park Hotels & Resorts (PK) has quietly lagged the broader market this year, and that underperformance has investors asking whether the stock is now a value opportunity or a value trap.\nSee our latest analysis for Park Hotels & Resorts.\nAt around $10.79, Park Hotels & Resorts reflects a year to date share price return of negative 21.7 percent. Its three year total shareholder return of 28.3 percent suggests longer term holders have still come out ahead, which may indicate that recent weakness...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9621070-choice1-main-header/1585186786447","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9621070-choice1-main-header/1585186786447"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate/nyse-pk/park-hotels-resorts/news/assessing-park-hotels-resorts-pk-valuation-after-recent-shar","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate/nyse-pk/park-hotels-resorts/news/assessing-park-hotels-resorts-pk-valuation-after-recent-shar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PK"],"gpt_icon":0},{"id":"2592918932","title":"SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918932","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918932?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976400,"startTime":"0","endTime":"0","summary":"Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteersStudy results support the chronic dosing o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/17/3206921/0/en/SAB-BIO-Announces-Positive-Confirmatory-Clinical-Results-from-the-Phase-1-Study-of-SAB-142-in-Development-for-the-Treatment-of-Stage-3-T1D.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","PK","SSI","BK4218","BK4023","BK4588","BIO","BK4585","LU1169590202.USD","LU1169589451.USD","BK4181","PD"],"gpt_icon":0},{"id":"2590473558","title":"GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590473558","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590473558?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400700,"startTime":"0","endTime":"0","summary":"Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used w","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3203497/0/en/GRI-Bio-Announces-Positive-Topline-Data-from-its-Phase-2a-Study-in-Idiopathic-Pulmonary-Fibrosis-IPF.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","BK4218","GRI","FVC","BK4181","PK"],"gpt_icon":0},{"id":"2590345947","title":"Park Hotels & Resorts to Sell Three More Non-Core Properties, Reaffirms 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2590345947","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590345947?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:19","pubTimestamp":1765282761,"startTime":"0","endTime":"0","summary":"Park Hotels & Resorts  said Tuesday that it plans to sell three additional non-core hotels by the end of the year, after agreeing to sell five non-core properties for gross proceeds of $198 million so far this year.The company said the three non-core hotels slated for sale are on expiring ground leases and include the 266-room Embassy Suites Kansas City Plaza, the 850-room DoubleTree Hotel Seattle Airport, and the 245-room DoubleTree Hotel Sonoma Wine Country.Park said it had already sold the 316-room Hyatt Centric Fisherman's Wharf in May and a 559-room joint venture interest in the Capital Hilton DC last month, with three of the five remaining transactions expected to close by early next year.The company said it expects to dispose of its remaining marketable non-core hotels over the next 12 months, completing its portfolio transformation.The company reaffirmed its 2025 outlook, with October and preliminary November comparable RevPAR largely in line with expectations, despite a slight","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PK","BK4218","BK4181"],"gpt_icon":0},{"id":"2590348943","title":"BRIEF-Park Hotels & Resorts Announces The Sale Of Additional Non-Core Hotels","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348943","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590348943?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:33","pubTimestamp":1765279997,"startTime":"0","endTime":"0","summary":"BRIEF-Park Hotels & Resorts Announces The Sale Of Additional Non-Core Hotels Dec 9 (Reuters) - Park Hotels & Resorts Inc PK.N:PARK HOTELS & RESORTS ANNOUNCES THE SALE OF ADDITIONAL NON-CORE HOTELS AND","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA2BVYMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","BK4181","BK4218"],"gpt_icon":0},{"id":"2590348981","title":"Park Hotels & Resorts Sells Five Non-Core Hotels for $198 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348981","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590348981?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:30","pubTimestamp":1765279838,"startTime":"0","endTime":"0","summary":"Park Hotels & Resorts Inc. announced the sale or agreements to sell five non-core hotels for approximately $198 million in gross proceeds at an average multiple of nearly 43x. Completed transactions include the sale of the Hyatt Centric Fisherman's Wharf and a joint venture interest in the Capital Hilton DC. Three additional hotel sales are expected to close by early 2026, as the company continues its strategy to divest underperforming non-core properties.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Park Hotels & Resorts Inc. published the original content used to generate this news brief via Business Wire  on December 09, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL9bLzzl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","PK","BK4181"],"gpt_icon":0},{"id":"2590348993","title":"Park Hotels & Resorts Inc: Reaffirms FY 2025 Outlook With Oct and Prelim Nov Comparable Revpar Results Largely in Line With Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590348993?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:30","pubTimestamp":1765279800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA2BVYMY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PK","BK4181","BK4218"],"gpt_icon":0},{"id":"2590348546","title":"Park Hotels & Resorts Announces the Sale of Additional Non-Core Hotels and Provides Update on Non-Core Hotel Disposition Activity and Recent Operating Trends","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348546","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590348546?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:30","pubTimestamp":1765279800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA2BVYMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4218","PK","BK4181"],"gpt_icon":0},{"id":"1105120926","title":"Three Leading Jiangsu City Commercial Banks Compared: Bank of Jiangsu Leads in Profit, Bank of Nanjing in Revenue Growth, Bank of Suzhou in Risk Control","url":"https://stock-news.laohu8.com/highlight/detail?id=1105120926","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105120926?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:00","pubTimestamp":1764936036,"startTime":"0","endTime":"0","summary":"In the first three quarters of 2025, all three listed city commercial banks in Jiangsu province reported positive growth. Among them, Bank of Nanjing (601009) ranked first in revenue growth, while...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001051.SGD","LU1979443071.USD","002966","SGXZ81163826.USD","BK0278","BK0028","BK0183","601009","BK0187","BK4218","SG9999002950.SGD","BK0188","BK0012","600919","BK4181","PK","SGXZ49509284.SGD","LU1934453819.USD","SG9999001226.SGD","SGXZ90724238.SGD"],"gpt_icon":0},{"id":"2588788726","title":"Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities","url":"https://stock-news.laohu8.com/highlight/detail?id=2588788726","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588788726?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:00","pubTimestamp":1764856800,"startTime":"0","endTime":"0","summary":"Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz over treatment area of 240 cm2Completion of this study marks a key milestone towards","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/04/3199836/0/en/Last-Patient-Completes-Biofrontera-s-Phase-1-Pharmacokinetics-Study-of-Ameluz-for-Treatment-of-Actinic-Keratoses-on-the-Trunk-and-Extremities.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDT","BK4007","BK4218","BK4181","BFRI","PK"],"gpt_icon":0},{"id":"2588882818","title":"Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia","url":"https://stock-news.laohu8.com/highlight/detail?id=2588882818","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588882818?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853200,"startTime":"0","endTime":"0","summary":"Study to evaluate safety and efficacy of novel anti-PRLR antibody; interim data anticipated in the second half of 2026 Trial design leverages operational synergies to enable accelerated registrational","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/04/3199743/0/en/Absci-Announces-First-Participants-Dosed-in-Phase-1-2a-HEADLINE-Trial-of-AI-Designed-Antibody-ABS-201-for-Androgenetic-Alopecia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AI","BK4023","PD","PK","LU1169590202.USD","LU1169589451.USD","BK4218","BK4181"],"gpt_icon":0},{"id":"2588378889","title":"Truist Raises Price Target on Park Hotels & Resorts to $12 From $11, Keeps Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2588378889","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588378889?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:59","pubTimestamp":1764849579,"startTime":"0","endTime":"0","summary":"Park Hotels & Resorts (PK) has an average rating of hold and mean price target of $11.73, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4181","PK","BK4218"],"gpt_icon":0},{"id":"2588030390","title":"Press Release: Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2588030390","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588030390?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:00","pubTimestamp":1764676800,"startTime":"0","endTime":"0","summary":"-- Extends cash runway through at least the first half of 2028. -- Led by healthcare-dedicated investors, including Vivo Capital, Janus. Investments, Adage Capital Partners and Squadron Capital Management. MIAMI, Dec. 02, 2025  -- Pasithea Therapeutics Corp.  , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas , today announced the closing of its previously announced public offering of 80,000,000 shares of the Company's common stock  at an offering price of $0.75 per share of common stock . The public offering was led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Management.H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.This press release does not constitute an offer to sell or the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"7a5901a9f1bb5fc4fa7bc7230f7ede9b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","BK4218","BK4023","BK4139","BK4181","LU1169590202.USD","KTTA","PD","PK"],"gpt_icon":1},{"id":"2588035413","title":"Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588035413","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588035413?lang=en_us&edition=fundamental","pubTime":"2025-12-02 17:00","pubTimestamp":1764666000,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ --Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration  has approved the investigational new drug  application for the Phase Ib/II CLINCH-2 study evaluating ATG-022  in combination with MSD's  anti-PD-1 therapy, KEYTRUDA , as well as ATG-022 in combination with pembrolizumab and chemotherapy.CLINCH-2 is a Phase Ib/II study that will be led by its principal investigator Prof. Lin Shen at Beijing Cancer Hospital, the lead trial center. The study is designed to evaluate two combination regimens in patients with CLDN18.2-positive, HER2-negative, and PD-L1-positive  unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma","market":"us","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-announces-ind-approval-in-china-for-phase-ibii-study-of-atg-022-cldn18-2-adc-in-combination-with-keytruda-pembrolizumab--chemotherapy-302630014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","ADC","IE00B66KJ199.SGD","CRS","LU0963586101.USD","BK4181","BK4080","IE00B7SZL793.SGD","ORR","IND","CRS.AU","BK4187","ORR.AU","IE0031619046.USD","PK","IND.AU","LU2065731478.USD","BK4006","ADC.AU","IE00B19Z4B17.USD","BK7095","BK4218"],"gpt_icon":0},{"id":"2588389779","title":"Park Hotels & Resorts Is Maintained at Equal-Weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2588389779","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588389779?lang=en_us&edition=fundamental","pubTime":"2025-12-01 23:16","pubTimestamp":1764602160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 01, 2025 10:16 ET (15:16 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765489.SGD","LU0048573561.USD","IE000M9KFDE8.USD","LU0868494617.USD","LU1267930227.SGD","LU1506573853.SGD","LU0162691827.USD","LU2361044865.SGD","LU0154236417.USD","BK4218","BK4585","LU0417517546.SGD","LU0942090050.USD","LU1267930490.SGD","LU2361044949.HKD","LU1267930573.SGD","IE0002270589.USD","LU0175139822.USD","LU0477156953.USD","LU0683600562.USD","LU0128525929.USD","LU1280957306.USD","LU0130102774.USD","LU0072461881.USD","LU0971096721.USD","LU0267386448.USD","LU0211327993.USD","PK","LU1201861249.SGD","LU0130517989.USD","LU0289960550.SGD","LU0106831901.USD","BK4588","BK4207","LU0211328371.USD","LU1035773651.USD","LU0128525689.USD","LU0310800965.SGD","IE00B19Z3581.USD","LU1069347547.HKD","LU2361045086.USD","LU0070302665.USD","IE00B7SZLL34.SGD","LU0742534661.SGD","LU0149725797.USD","LU2236285917.USD","LU1791807156.HKD","BK4504","LU0787776722.HKD","LU0648001328.SGD"],"gpt_icon":0},{"id":"2588223137","title":"ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588223137","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588223137?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590400,"startTime":"0","endTime":"0","summary":"Cambridge, Massachusetts, Dec.  01, 2025  (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s dise","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196854/0/en/ProMIS-Neurosciences-to-Participate-in-the-8th-Annual-Evercore-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","LU2211815571.USD","LU0728928796.USD","BK4137","LU1923622291.USD","LU1815336091.USD","BK4585","BK4588","BK4595","BK4023","XBI","LU0029874061.USD","BK4143","ARIA","BK4218","XLV","AD","LU2125909916.SGD","LU2125909759.SGD","BK4526","BK4581","MSA","LU0128526141.USD","BK4600","LU0757428866.USD","LABU","LU1169589451.USD","PK","LU0053671581.USD","PD","LU1169590202.USD","HCSG","BK4170","USA","BK4181"],"gpt_icon":1},{"id":"2588223127","title":"Akebia Announces Establishment of Rare Kidney Disease Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2588223127","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588223127?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590400,"startTime":"0","endTime":"0","summary":"Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease ind","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196841/37519/en/Akebia-Announces-Establishment-of-Rare-Kidney-Disease-Pipeline.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BK4585","BK4181","BK4588","BK4077","FSGS","LU1169589451.USD","BK4213","BK4157","PD","BK4023","MACE","LU0256331488.USD","PK","RBC","BK4183","IE00BLDYK493.USD","APA","LU2065731478.USD","MI","LU1169590202.USD","IE00B64QTZ34.USD","BK4218"],"gpt_icon":0},{"id":"2586334247","title":"Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2586334247","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586334247?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:20","pubTimestamp":1764339600,"startTime":"0","endTime":"0","summary":"Extends cash runway through at least the first half of 2028Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/28/3196323/0/en/Pasithea-Therapeutics-Announces-Pricing-of-60-Million-Public-Offering-of-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","KTTA","BK4218","PD","LU1169589451.USD","BK4023","BK4139","BK4181","LU1169590202.USD"],"gpt_icon":0},{"id":"1174567935","title":"Alphabet vs NVIDIA Ignites Optical Module Sector: Is This the First Step in Rebuilding A-Share Tech Consensus?","url":"https://stock-news.laohu8.com/highlight/detail?id=1174567935","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174567935?lang=en_us&edition=fundamental","pubTime":"2025-11-27 18:51","pubTimestamp":1764240700,"startTime":"0","endTime":"0","summary":"The market is currently attempting to rebuild consensus around the tech sector. As Alphabet and NVIDIA continue to diverge in their technological roadmaps, capital is flowing toward \"computing arms...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0107464264.USD","BK4605","LU0942090050.USD","LU0861579265.USD","LU0345769631.USD","LU0347712357.USD","LU0011850046.USD","LU0320765059.SGD","LU2272731782.SGD","LU0689626769.HKD","IE00BKPKM429.USD","BK4587","LU0345774391.USD","LU0345769128.USD","LU1699723380.USD","NVDA","LU2236285917.USD","LU2417539215.USD","LU1032955483.USD","LU2275660780.HKD","LU1992135399.USD","BK4608","LU2106854487.HKD","LU2168564149.EUR","LU2083900584.USD","IE00B19Z8X17.USD","LU0234572021.USD","LU1868837136.USD","LU0106261372.USD","BK4567","BK4533","LU2433249047.HKD","IE00BFXG0V08.USD","LU2237443622.USD","LU1066053197.SGD","LU1951200564.SGD","LU2506951792.HKD","LU0354030511.USD","LU0149725797.USD","LU0965509010.AUD","LU0314104364.USD","LU2023250504.SGD","LU2413666699.HKD","HK0000320223.HKD","PK","IE00B775SV38.USD","LU0130102774.USD","LU1037948541.HKD","LU0061474705.USD","IE00BDRTCR15.USD","LU1804176565.USD","IE00BMPRXR70.SGD","LU0878866978.SGD","LU0265550946.USD","SG9999002224.SGD","LU2360106780.USD","LU0494093205.USD","LU1066051498.USD","NVD3.UK","LU1430594728.SGD","LU2125154935.USD","LU1674673428.USD","LU0648000940.SGD","LU0690374961.EUR","LU0267386448.USD","BK4588","LU2237443382.USD","LU2756315664.SGD","LU0124676726.USD","LU2471134952.CNY","LU1989764748.USD","LU1861215975.USD","LU0433182093.SGD","IE00B19Z9505.USD","LU1868836914.USD","LU0528227936.USD","LU2237438978.USD","IE0004445015.USD","LU1935042991.SGD","IE00BQXX3F31.USD","IE0004086264.USD","LU1064131342.USD","LU0056508442.USD","SG9999014567.USD","BK4543","LU1037948897.HKD","LU0786609619.USD","IE00BQXX3D17.EUR","SG9999015341.SGD","SG9999014575.USD","LU1989772840.SGD","LU1935043536.SGD","2NVD.UK","LU0390134368.USD","LU0203201768.USD","LU1868837300.USD","NVDL","BK4549","LU0208291251.USD","LU1989764664.SGD","LU0109392836.USD","LU1261432733.SGD","LU2272731600.USD","LU0823421416.USD","LU0985320562.USD","LU2471134796.USD","LU0265550359.USD","LU0310800965.SGD","LU2552382215.SGD","LU0211327993.USD","LU0128525929.USD","BK4602","LU0096362180.USD","LU2360032135.SGD","LU1267930813.SGD","LU2065171311.SGD","LU1914381329.SGD","LU0342679015.USD","LU2191332357.HKD","LU1435385759.SGD","LU2237443978.SGD","LU1791710400.SGD","LU2125909759.SGD","LU1791710582.SGD","LU0965509101.SGD","LU1989772923.USD","LU2381873111.SGD","LU1489326972.SGD","LU0289961442.SGD","LU0353189763.USD","LU1880398554.USD","BK4574","LU2065169927.USD","LU1074936037.SGD","LU2065170008.USD","LU1718418525.SGD","BK4503","LU2362540622.SGD","BK4581","LU0957791311.USD","LU2125154778.USD","LU2023250330.USD","IE00BJJMRX11.SGD","LU1301847155.USD","LU2720916845.USD","LU2290526834.HKD","LU2543165471.USD","BK4514","LU1821325948.USD","IE00BSNM7G36.USD","LU1506573853.SGD","LU0289960550.SGD","LU1429558221.USD","LU1623119135.USD","LU0345768740.USD","IE00BQXX3C00.GBP","LU0354030438.USD","BK4077","LU2357305700.SGD","IE00B1BXHZ80.USD","BK4529","LU1153585028.USD","LU1934455194.USD","LU1852331112.SGD","NVIW.SI","LU1720051108.HKD","LU1003077747.HKD","LU0353189680.USD","LU1127390331.HKD","LU2463028550.USD","SG9999017495.SGD","LU0198837287.USD","IE00B775H168.HKD","BK4141","BK4585","LU2264538146.SGD","LU1035773651.USD","LU1035775433.USD","LU2265009873.SGD","LU0345770308.USD","IE0002270589.USD","LU0965508806.USD","LU2111349929.HKD","LU1803068623.USD","LU0081259029.USD","LU0053666078.USD","IE00BKDWB100.SGD","NVDS.UK","SGXZ23171101.USD","LU2242650005.HKD","LU0238689110.USD","LU1923622614.USD","LU0949170426.SGD","NVDD","LU0210533765.USD","IE00B3M56506.USD","IE00BN29S564.USD","LU0158827948.USD","LU0158827781.USD","IE00BHPRN162.USD","LU1242518857.USD","LU1633808545.USD","SG9999015358.SGD","LU0444973449.USD","LU1244550494.USD","LU1551013342.USD","LU1861220033.SGD","BK4527","BK4507","LU1235294995.USD","LU2750360641.GBP","LU1894683264.USD","LU2896262040.SGD","LU0965509283.SGD","LU1935042215.USD","IE00BD6J9T35.USD","GB00B4LPDJ14.GBP","LU1232071149.USD","LU1323610961.USD","LU2092937148.SGD","LU0557290698.USD","LU2294711713.HKD","LU2097344431.USD","LU1951198990.SGD","LU2211815571.USD","IE00B5TLWC47.USD","LU2087621335.USD","LU2362541513.USD","IE00BLSP4239.USD","LU2487616109.SGD","LU2271345857.HKD","LU2272731865.HKD","LU0683600562.USD","LU1066051225.USD","LU2249611893.SGD","IE0001KFT4U8.USD","LU1496350171.SGD","LU2250418816.HKD","IE0034235303.USD","LU0082616367.USD","LU2404859741.USD","LU0289941410.SGD","NVD","LU0964807845.USD","NVDS","BK4534","LU0080751232.USD","LU1316542783.SGD","BK4566","IE00B19Z3581.USD","IE00BJTD4N35.SGD","LU0417517546.SGD","LU0130103400.USD","LU2430703251.USD","IE00BZ199S13.USD","LU1267930730.SGD","LU1721428933.USD","LU1116320737.USD","LU2505996681.GBP","BK4218","LU0289739343.SGD","LU0949170772.SGD","LU1935043023.USD","LU2242649171.HKD","LU2089985449.USD","LU2357125470.USD","IE00B7KXQ091.USD","IE00BK4W5M84.HKD","LU0266013472.USD","LU0788109477.HKD","LU0889566641.SGD","IE0009356076.USD","SG9999015986.USD","LU0787776722.HKD","IE00BFSS7M15.SGD","IE00BFSS8Q28.SGD","IE00BYQQ9H92.USD","LU2097829019.USD","LU2087625088.SGD","IE00BK4W5L77.USD","LU1712237335.SGD","LU2403377893.USD","LU2420271590.USD","LU2168564065.EUR","LU2746668974.SGD","LU2491049909.HKD","LU0784385170.HKD","LU2505996509.AUD","LU0068578508.USD","LU1868836757.USD","SGXZ99366536.SGD","LU0784384876.USD","LU0314106906.USD","SG9999014880.SGD","BK4525","LU0792757196.USD","LU1121112475.USD","LU0203345920.USD","LU0308772762.SGD","LU0211328371.USD","LU0823434583.USD","LU1267930227.SGD","LU2452424414.USD","LU0251142724.SGD","LU2098885051.SGD","IE00BLSP4452.SGD","BK4181","LU2764262908.HKD","LU1814569148.SGD","IE00BMPRXQ63.HKD","BK4561","LU1923623000.USD","IE0004445239.USD","LU2592432038.USD","LU0061474960.USD","LU0203347892.USD","LU1366333091.USD","LU0276348264.USD","LU2322448791.USD","LU2237957902.USD","LU0820561818.USD","BK4553","IE00BKVL7J92.USD","LU1691799644.USD","LU0072462426.USD","LU0545039389.USD","LU1923622291.USD","SGXZ81514606.USD","LU2168564222.USD","BK4598","IE0034235295.USD","GB00BDT5M118.USD","LU0823421333.USD","LU0057025933.USD","SGXZ31699556.SGD","SGXZ51526630.SGD","LU0256863902.USD","IE00BMPRXN33.USD","LU0724617625.USD","BK4548","LU0127658192.USD","LU0456855351.SGD","3NVD.UK","LU1059921491.USD","LU2237443549.SGD","LU1066051811.HKD","LU0210536198.USD","LU0784383803.USD","LU0070217475.USD","NVDY","LU0742534661.SGD","IE00BN8TJ469.HKD","BK4550","159982","LU2491050154.USD","LU0211331839.USD","GOOG","IE00BDCRKT87.USD","LU0052756011.USD","LU0128525689.USD","LU2237443465.HKD","LU0868494708.USD","LU1815336760.USD","LU2092627202.USD","LU0553294199.USD","LU0345768153.USD","IE00BJJMRY28.SGD","LU0048584097.USD","LU1221951129.SGD","LU2764263039.SGD","LU0215105999.USD","IE00B19Z8W00.USD","LU0256863811.USD","LU2361044949.HKD","LU0187121727.USD","LU2065171402.SGD","LU0345770993.USD","LU0109391861.USD","LU2028103732.USD","IE00BBT3K403.USD","LU0426412945.USD","LU1119994496.HKD","NVDX","LU0784385840.USD","LU0882574139.USD","BK4538","LU1244550221.USD","SG9999018865.SGD","IE00BZ1G4Q59.USD","IE00B1XK9C88.USD","LU0097036916.USD","LU0225283273.USD","LU2362541273.HKD","LU2552382058.USD","IE00BYXW3230.USD","LU2322448957.HKD","LU0130518102.USD","LU0316494557.USD","LU1280957306.USD","LU0708994859.HKD","SG9999015952.SGD","LU2237443895.HKD","LU1201861249.SGD","LU0823414551.USD","LU2077746001.SGD","SG9999001424.SGD","LU2456880835.USD","LU1674673691.USD","LU2404859667.USD","LU1839511570.USD","LU0157215616.USD","LU2125909916.SGD","LU1823568750.SGD","LU0472753341.HKD","LU2023250843.SGD","LU0477156797.USD","LU0957808578.USD","HK0000306701.USD","LU0006306889.USD","LU0310799852.SGD","BK4551","LU0820562030.AUD","LU2491050071.SGD","LU2750360997.AUD","LU0689472784.USD","LU2413666426.HKD","IE00B5949003.HKD","LU2125909593.SGD","LU2860962120.EUR","LU1720051017.SGD","LU1983260115.SGD","LU1548497426.USD","LU0079474960.USD","LU1196500208.SGD","SG9999002232.USD","LU0943347566.SGD","LU0348723411.USD","LU2213496289.HKD","LU0889565833.HKD","LU1585245621.USD","LU0708995401.HKD","LU2756315318.SGD","LU1868836591.USD","SG9999014542.SGD","LU1084165304.USD","IE00B19Z3B42.SGD","LU1571399168.USD","LU2360107168.USD","LU0719512351.SGD","LU2430703095.HKD","IE00BWXC8680.SGD","SG9999014914.USD","BK4592","LU1043141396.HKD","LU2237957811.SGD","LU0175139822.USD","LU1267930490.SGD","LU0234570918.USD","GOOGL","LU0203202063.USD","SG9999000418.SGD","LU2931357623.SGD","LU1366192091.USD","LU1629891620.HKD","LU1267930573.SGD","IE0034235188.USD","LU1069344957.HKD","LU1988902786.USD","LU0477156953.USD","IE00B3S45H60.SGD","HK0000320264.USD","LU1244550577.SGD","SG9999018857.SGD","LU1815333072.USD","IE0004091025.USD","LU1934455863.HKD","LU2063271972.USD","LU2247934214.USD","LU0511384066.AUD","LU0061475181.USD","LU1934455277.USD","NVD2.UK","LU0251131958.USD","LU0154236417.USD","LU0979878070.USD","LU0426417589.USD","IE00BFMHRM44.USD","LU0823434740.USD","LU0029864427.USD","LU0251132253.USD","LU2471134523.USD","SG9999014906.USD","LU1992135472.HKD","LU0094547139.USD","LU1642822529.SGD","LU2097344357.USD","IE00BJTD4V19.USD","LU1551013425.SGD","LU1935042488.USD","LU2054465674.USD","LU1894683348.USD","LU0823414478.USD","LU0985489474.SGD","LU2602419157.SGD","USJW.SI","LU0048573561.USD","LU1221951046.USD","HK0000306685.HKD","LU2361044865.SGD","IE0005OL40V9.USD","SG9999015978.USD","LU2168564495.EUR","LU0345774631.USD","LU2764263203.CNY","LU1670628061.USD","LU0210528500.USD","LU2089284900.SGD","LU2746668461.USD","LU0690374615.EUR","LU0323591593.USD","NVDU","SG9999014898.SGD","LU2108987350.USD","LU2168563687.JPY","LU2458330169.SGD","LU2089283258.USD","BK4612","IE00B4JS1V06.HKD","LU0096364046.USD","LU1242518931.SGD","LU1670627923.USD","LU2458330243.SGD","LU1201861165.SGD","LU0476273544.USD","SNVD.UK","399300","LU1803068979.SGD","LU0868494617.USD","LU0077335932.USD","LU1303367103.USD","SG9999004303.SGD","SG9999014559.SGD","LU2430703178.SGD","BK4554","LU2473716301.USD","LU0980610538.SGD","BK4532","LU1861127337.USD","LU1069347547.HKD","LU2471134879.HKD","LU2286300806.USD","LU1496350502.SGD","LU0070302665.USD","LU0312595415.SGD","LU2461242641.AUD","BK4576","LU0170899867.USD","BK4614","LU0994945656.USD","LU1778281490.HKD","LU1046421795.USD","LU1974910355.USD","LU0444971666.USD","IE00BJLML261.HKD","LU0820561909.HKD","LU0738911758.USD","LU0672654240.SGD","LU0302445910.USD","LU1145028129.USD","LU2023251221.USD","LU2326559502.SGD","SG9999015945.SGD","LU0069063385.USD","LU0274383776.USD","LU0661504455.SGD","LU0130517989.USD","BK4573","LU1917777945.USD","LU2552382132.HKD","LU2125909247.SGD","LU0466842654.USD","LU2244417387.USD","SG9999001077.SGD","LU2462157665.USD","LU2361045086.USD","LU0320765489.SGD","LU1880398471.USD","GB00B4QBRK32.GBP","LU0648001328.SGD","LU1116320901.HKD","LU1043141123.HKD","LU0310800379.SGD","BK4579","LU0640476718.USD","LU0642271901.SGD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.pkhotelsandresorts.com","stockEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":0.0009},{"period":"3month","weight":-0.059},{"period":"6month","weight":0.0294},{"period":"1year","weight":-0.2802},{"period":"ytd","weight":-0.2296}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":0.0156},{"period":"3month","weight":0.043},{"period":"6month","weight":0.1226},{"period":"1year","weight":0.148},{"period":"ytd","weight":0.1778}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Park is one of the largest publicly-traded lodging REITs with a diverse portfolio of iconic and market-leading hotels and resorts with significant underlying real estate value. Park's portfolio currently consists of 46 premium-branded hotels and resorts with over 29,000 rooms primarily located in prime city center and resort locations.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":0.017466},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.000424},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.075131},{"month":4,"riseRate":0.555556,"avgChangeRate":0.018945},{"month":5,"riseRate":0.555556,"avgChangeRate":-0.003955},{"month":6,"riseRate":0.222222,"avgChangeRate":-0.036956},{"month":7,"riseRate":0.555556,"avgChangeRate":-0.003154},{"month":8,"riseRate":0.555556,"avgChangeRate":0.010156},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.027085},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.018341},{"month":11,"riseRate":0.777778,"avgChangeRate":0.119029},{"month":12,"riseRate":0.555556,"avgChangeRate":-0.003978}],"exchange":"NYSE","name":"Park Hotels & Resorts Inc.","nameEN":"Park Hotels & Resorts Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Park Hotels & Resorts Inc.(PK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Park Hotels & Resorts Inc.(PK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Park Hotels & Resorts Inc.,PK,Park Hotels & Resorts Inc.股票,Park Hotels & Resorts Inc.股票老虎,Park Hotels & Resorts Inc.股票老虎国际,Park Hotels & Resorts Inc.行情,Park Hotels & Resorts Inc.股票行情,Park Hotels & Resorts Inc.股价,Park Hotels & Resorts Inc.股市,Park Hotels & Resorts Inc.股票价格,Park Hotels & Resorts Inc.股票交易,Park Hotels & Resorts Inc.股票购买,Park Hotels & Resorts Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Park Hotels & Resorts Inc.(PK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Park Hotels & Resorts Inc.(PK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction